Atossa Therapeutics, Inc. (NASDAQ:ATOS) Director Jonathan Finn Buys 25,000 Shares : vimarsana.com

Atossa Therapeutics, Inc. (NASDAQ:ATOS – Get Free Report) Director Jonathan Finn bought 25,000 shares of the stock in a transaction that occurred on Wednesday, April 10th. The shares were purchased at an average cost of $1.77 per share, with a total value of $44,250.00. Following the purchase, the director now directly owns 25,000 shares of […]

Related Keywords

Jonathan Finn , Cantor Fitzgerald , Charles Schwab Investment Management Inc , Nasdaq , Sigma Securities , First Republic Investment Management Inc , Atossa Therapeutics Company Profile , Atossa Therapeutics Inc , Northern Trust Corp , Jpmorgan Chase Co , Securities Exchange Commission , Atossa Therapeutics , Get Free Report , Director Jonathan Finn , Exchange Commission , Republic Investment Management , Trust Corp , Schwab Investment Management , Two Sigma Securities , Atossa Therapeutics Daily , Nasdaq Atos , Atos , Medical , Insider Trading , Nsider Trades , Tocks ,